Research progress and treatment strategies of intestinal immune factors in inflammatory bowel disease

doi:10.3760/cma.j.issn.1007-1245.2024.04.011

Abstract

Abstract:

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease caused by a variety of causes. In recent years, with the deepening of research, intestinal immune factors have gradually been paid attention to by clinical and researchers, providing an emerging research direction for IBD. We have traced related literature researches in the domestic and foreign medical databases such as PubMed/Medline/Cochrane/SinoMed/CNKI/Wanfang/CQVIP in the past 20 years, and summarize the mechanisms of intestinal nutrition, intestinal microenvironment, intestinal oxygen supply, intestinal immune factors, and circadian rhythm involved in the pathogenesis of IBD, in order to explore new therapeutic targets and lay a foundation for further study of IBD.

Key words:

Inflammatory bowel disease, Immunity, Research progress

摘要：

炎症性肠病（inflammatory bowel disease，IBD）是由多种因素导致的肠道慢性炎症。近年来，随着研究的不断深入，肠道免疫因素逐渐受到临床及科研工作者的重视，为IBD的诊断和治疗提供了新兴研究方向。本文通过PubMed/Medline/Cochrane/SinoMed/知网/万方/维普等国内外医学数据库追溯了近20年的相关文献研究，对国内外文献中的肠道营养、肠道微环境、肠道氧供、肠道免疫因子以及昼夜节律等参与IBD发病的作用机制进行总结，旨在探索新的治疗靶点，为IBD的深入研究奠定基础。

关键词:

炎症性肠病, 免疫, 研究进展

Pan Guangtao, Chen Aiying.

Research progress and treatment strategies of intestinal immune factors in inflammatory bowel disease [J]. International Medicine and Health Guidance News, 2024, 30(4): 577-581.

潘广涛陈爱莹.

肠道免疫因素在炎症性肠病中的研究进展及治疗策略 [J]. 国际医药卫生导报, 2024, 30(4): 577-581.

References

[1] Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet, 2007, 369(9573):1627-1640. DOI: 10.1016/S0140-6736(07)60750-8.
[2] Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density[J]. Arq Bras Endocrinol Metabol, 2008, 52(4):684-691. DOI: 10.1590/s0004-27302008000400015.
[3] Verway M, Behr MA, White JH. Vitamin D, NOD2, autophagy and Crohn's disease[J]. Expert Rev Clin Immunol, 2010, 6(4):505-508. DOI: 10.1586/eci.10.31.
[4] Polidoro L, Properzi G, Marampon F, et al. Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation[J]. J Cardiovasc Transl Res, 2013, 6(2):221-231. DOI: 10.1007/s12265-012-9436-x.
[5] Konijeti GG, Arora P, Boylan MR, et al. Vitamin D supplementation modulates T cell-mediated immunity in humans: results from a randomized control trial[J]. J Clin Endocrinol Metab, 2016, 101(2):533-538. DOI: 10.1210/jc.2015-3599.
[6] Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294(1):G208-G216. DOI: 10.1152/ajpgi.00398.2007.
[7] Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2014, 39(2):125-136. DOI: 10.1111/apt.12553.
[8] Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity[J]. J Mol Med (Berl), 2010, 88(5):441-450. DOI: 10.1007/s00109-010-0590-9.
[9] Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease[J]. J Nutr, 2000, 130(11):2648-2652. DOI: 10.1093/jn/130.11.2648.
[10] Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study[J]. Aliment Pharmacol Ther, 2010, 32(3):377-383. DOI: 10.1111/j.1365-2036.2010.04355.x.
[11] Mathur J, Naing S, Mills P, et al. A randomized clinical trial of vitamin D3 (cholecalciferol) in ulcerative colitis patients with hypovitaminosis D3[J]. PeerJ, 2017, 5:e3654. DOI: 10.7717/peerj.3654.
[12] Siva S, Rubin DT, Gulotta G, et al. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2017, 23(1):152-157. DOI: 10.1097/MIB.0000000000000989.
[13] Cleynen I, Vazeille E, Artieda M, et al. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease[J]. Gut, 2014, 63(8):1265-1274. DOI: 10.1136/gutjnl-2012-303205.
[14] Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(2):110-121. DOI: 10.1038/nrgastro.2016.181.
[15] McLaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing[J]. Ann Surg, 2010, 252(1):90-98. DOI: 10.1097/SLA.0b013e3181e3dc8b.
[16] Boirivant M, Cossu A. Inflammatory bowel disease[J]. Oral Dis, 2012, 18(1):1-15. DOI: 10.1111/j.1601-0825.2011. 01811.x.
[17] el-Omar E, Penman I, Cruikshank G, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine[J]. Gut, 1994, 35(10):1385-1388. DOI: 10.1136/gut.35.10.1385.
[18] Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease[J]. J Crohns Colitis, 2014, 8(6):443-468. DOI: 10.1016/j.crohns.2013.12.013.
[19] 陈小丽,万珊珊,曹倩.炎症性肠病住院患者216例的难辨梭状芽孢杆菌感染危险因素和预后[J].中华消化杂志,2017,37(4):238-243. DOI:10.3760/cma.j.issn.0254-1432.2017. 04.004.
[20] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病合并机会性感染专家共识意见[J].中华消化杂志,2017,37(4):217-226. DOI:10.3760/cma.j.issn.0254-1432.2017. 04.001.
[21] Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis[J]. Am J Gastroenterol, 2012, 107(12):1913-1922. DOI: 10.1038/ajg.2012.335.
[22] Schwiertz A, Jacobi M, Frick JS, et al. Microbiota in pediatric inflammatory bowel disease[J]. J Pediatr, 2010, 157(2):240-244.e1. DOI: 10.1016/j.jpeds.2010.02.046.
[23] Zhang SL, Wang SN, Miao CY. Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention[J]. Front Immunol, 2017, 8:1674. DOI: 10.3389/fimmu.2017.01674.
[24] Tiratterra E, Franco P, Porru E, et al. Role of bile acids in inflammatory bowel disease[J]. Ann Gastroenterol, 2018, 31(3):266-272. DOI: 10.20524/aog.2018.0239.
[25] Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe, 2014, 15(3):382-392. DOI: 10.1016/j.chom.2014.02.005.
[26] Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease[J]. Inflamm Bowel Dis, 2009, 15(5):653-660. DOI: 10.1002/ibd.20783.
[27] Ferreira-Halder CV, Faria AVS, Andrade SS. Action and function of Faecalibacterium prausnitzii in health and disease[J]. Best Pract Res Clin Gastroenterol, 2017, 31(6):643-648. DOI: 10.1016/j.bpg.2017.09.011.
[28] Del Chierico F, Abbatini F, Russo A, et al. Gut microbiota markers in obese adolescent and adult patients: age-dependent differential patterns[J]. Front Microbiol, 2018, 9:1210. DOI: 10.3389/fmicb.2018.01210.
[29] Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice[J]. Cell Rep, 2014, 7(1):12-18. DOI: 10.1016/j.celrep.2014.02.032.
[30] Campbell EL, Bruyninckx WJ, Kelly CJ, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation[J]. Immunity, 2014, 40(1):66-77. DOI: 10.1016/j.immuni.2013.11.020.
[31] Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease[J]. Am J Physiol Heart Circ Physiol, 2003, 285(5):H1791-H1796. DOI: 10.1152/ajpheart.00552.2003.
[32] Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension[J]. Proc Natl Acad Sci U S A, 1995, 92(12):5510-5514. DOI: 10.1073/pnas.92.12.5510.
[33] Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases[J]. Nat Rev Mol Cell Biol, 2004, 5(5):343-354. DOI: 10.1038/nrm1366.
[34] Chowdhury R, Hardy A, Schofield CJ. The human oxygen sensing machinery and its manipulation[J]. Chem Soc Rev, 2008, 37(7):1308-1319. DOI: 10.1039/b701676j.
[35] Ortiz-Barahona A, Villar D, Pescador N, et al. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction[J]. Nucleic Acids Res, 2010, 38(7):2332-2345. DOI: 10.1093/nar/gkp1205.
[36] Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation[J]. J Clin Invest, 2022, 132(11):e159839. DOI: 10.1172/JCI159839.
[37] Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing[J]. Science, 2001, 292(5516):464-468. DOI: 10.1126/science.1059817.
[38] Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(10):596-611. DOI: 10.1038/nrgastro.2017.101.
[39] 杨勇,张巍.炎症性肠病免疫发病机制的研究进展[J].中国实验诊断学,2012,16(1):181-183. DOI:10.3969/j.issn.1007-4287.2012.01.079.
[40] 张亚姝,成海燕(综述),邹颖(审校).Th9细胞及其与炎症性肠病关系的研究进展[J].医学研究生学报,2016,29(12):1334-1339. DOI:10.16571/j.cnki.1008-8199.2016.12.023.
[41] Chen Z, Yu K, Zhu F, et al. Over-expression of CD200 protects mice from dextran sodium sulfate induced colitis[J]. PLoS One, 2016, 11(2):e0146681. DOI: 10.1371/journal.pone.0146681.
[42] West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease[J]. Nat Med, 2017, 23(5):579-589. DOI: 10.1038/nm.4307.
[43] Swanson GR, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare?[J]. Expert Rev Clin Immunol, 2011, 7(1):29-36. DOI: 10.1586/eci.10.83.
[44] Liang X, Bushman FD, FitzGerald GA. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock[J]. Proc Natl Acad Sci U S A, 2015, 112(33):10479-10484. DOI: 10.1073/pnas.1501305112.
[45] Tang X, Guo D, Lin C, et al. hCLOCK causes rho-kinase-mediated endothelial dysfunction and NF-κB-mediated inflammatory responses[J]. Oxid Med Cell Longev, 2015, 2015:671839. DOI: 10.1155/2015/671839.
[46] Yu X, Rollins D, Ruhn KA, et al. TH17 cell differentiation is regulated by the circadian clock[J]. Science, 2013, 342(6159):727-730. DOI: 10.1126/science.1243884.
[47] Arjona A, Sarkar DK. The circadian gene mPer2 regulates the daily rhythm of IFN-gamma[J]. J Interferon Cytokine Res, 2006, 26(9):645-649. DOI: 10.1089/jir.2006.26.645.
[48] 谢成,晏维,付妤.生物钟与炎症性肠病[J].临床消化病杂志,2016,28(6):390-393. DOI:10.3870/lcxh.j.issn.1005- 541X.2016.06.19.